SpaceX IPO Raises $75 Billion As Funds Trim Tech

SpaceX IPO reshaped tech-sector positioning as hedge-fund selling concentrated prelisting flows into linked vehicles and heightened index inclusion risk.

June 12, 2026·2 min read
View all news articles
Flat filled vector satellite dish with dimming signal lights against a smooth violet-mist gradient, evoking SpaceX IPO and shifting fund flows.

KEY TAKEAWAYS

  • Hedge funds trimmed large U.S. tech positions and added bearish bets ahead of the SpaceX IPO.
  • Offering priced 555.6 million shares at $135, raising about $75 billion and implying roughly $1.75 trillion valuation.
  • Destiny Tech100 drew focus and Nasdaq inclusion timing could trigger offsetting passive-fund flows.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

SpaceX began trading on Nasdaq under ticker SPCX on June 12, 2026, as hedge funds reduced exposure to large U.S. technology stocks ahead of the company’s IPO, concentrating premarket positioning around related investment vehicles.

Trading Debut and Hedge-Fund Positioning

The offering included 555.6 million shares priced at $135 each, implying a market valuation near $1.75 trillion. Shares opened at $150, about 11% above the IPO price, setting the tone for heavy attention to the listing’s size and aftermarket performance. Market participants noted that the combination of scale and an above-offer open would shape short-term trading dynamics.

Early on June 12, a JPMorgan research note showed hedge funds trimming positions in the largest U.S. technology stocks while adding some bearish bets ahead of the debut. This repositioning heightened focus on investment vehicles perceived to have exposure to SpaceX, notably Destiny Tech100 (DXYZ), as investors sought indirect ways to express views on the new public company.

The market also considered recent Nasdaq methodology changes that could affect the timing of index inclusion and related passive-fund flows. These overlapping factors—active hedge-fund selling and potential large passive inflows upon index inclusion—may push prices in opposite directions. The immediate post-debut price likely reflects how these forces interact alongside the market’s view of the company’s assumptions.

Valuation Concentrated in Starlink

Commentary highlighted SpaceX’s satellite business, Starlink, as central to the valuation. Analyst-style estimates placed Starlink revenue at about $12 billion with operating margins near 40%. The IPO priced SPCX at roughly 94 times projected 2025 revenue, a multiple sensitive to updates on Starlink’s growth and profitability.

Investors monitoring early trading and disclosures will weigh whether Starlink’s performance can sustain such high expectations, given its outsized contribution to the company’s revenue and profit profile.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

PepsiCo Earnings Show Revenue Gain and U.S. Weakness

PepsiCo Earnings Show Revenue Gain and U.S. Weakness

PepsiCo earnings saw revenue and international volumes rise but U.S. organic revenue fell and core EPS was modest, prompting traders to reassess guidance.

Micron U.S. Investment Plan Accelerates

Micron U.S. Investment Plan Accelerates

Micron U.S. investment plan accelerates after a Clay, New York milestone and could prompt traders to reprice DRAM capacity and supply-chain exposure.

Micron $3 Billion Investment Strengthens U.S. Chip Supply

Micron $3 Billion Investment Strengthens U.S. Chip Supply

Micron $3 Billion Investment announced July 9, 2026 to back GlobalWafers' U.S. wafer expansion and could tighten memory-supply positioning for traders.

Levi Strauss Q2 Earnings Beat, Raises Guidance

Levi Strauss Q2 Earnings Beat, Raises Guidance

Levi Strauss Q2 earnings beat consensus and the company raised FY 2026 guidance and its dividend, supporting buyback and dividend flows.

AstraZeneca Trial Failure Sends Shares Lower

AstraZeneca Trial Failure Sends Shares Lower

AstraZeneca trial failure in Phase 3 CARDIO-TTRansform left eplontersen short of its goal and triggered a roughly 9% share selloff on July 9, 2026.

SK Hynix Nasdaq Listing Draws Heavy Demand

SK Hynix Nasdaq Listing Draws Heavy Demand

SK Hynix Nasdaq listing will raise about $28 billion to fund HBM and AI capacity, likely concentrating investor demand and U.S. ADR flows.